infoTECH News

Dynex Technologies announced today it has conducted a successful field
trial of its patented M�™ Multiplexed Microwell system to
test for five different diseases with a single process as part of a
serosurvey program in the Democratic Republic of the Congo (DRC).
Dynex's MMRVT panel tested each patient for measles, mumps, rubella,
varicella and tetanus in the program under the direction of Dr. Anne
Rimoin, Associate Professor of Epidemiology at UCLA. These diseases
present a significant danger of child mortality and congenital
deformation of unborn children. The survey is designed to develop a
nationwide immunity profile, which in turn will be used to design
immunization programs within the DRC. In this work 40,000 respondents
will be surveyed with 8,000 children being tested for MMRVT immunity via
dried blood spot sample collection. The project is being funded by The
Bill and Melinda Gates Foundation in partnership with UCLA and
coordinated by the Kinshasa School of Public Health.

This summer, the first 807 dried blood spot samples were analyzed onsite
in Kinshasa using Dynex's patented M� multiplex technology. The M� assay
involves using a modified microwell plate, with the bottom of each well
embedded with 10 different positionally determined 2-millimeter diameter
polystyrene beads, with each bead activated for separate viral agents or
as in-well positive and negative controls. Samples taken from the dried
blood spots are then assayed for levels of several different antibodies
in a single well. The fully automated Dynex S2® immunoassay
processor performs the assay followed by data acquisition in a
chemiluminescent image analyzer, where 540 data points per completed
microplate are obtained and analyzed in less than two minutes. This
technology allows researchers to quickly and reliably determine exposure
and immunization effectiveness levels for a range of diseases using very
little sample, while also demonstrating the effectiveness of using dried
blood spots as a means of sampling. In contrast to whole blood draws,
which require more advanced training and equipment than is typically
available in impoverished areas, dried blood spots can be easily
obtained and transported without refrigeration.

Dr. Anne Rimoin, UCLA: "The M� technology from Dynex proved itself very
adaptable to the conditions of the samples and the environment in a low
resource, logistically challenging location like Kinshasa, allowing us
to achieve our goals of obtaining high quality results quickly, easily
and inexpensively, with a minimum amount of training."

Adrian Bunce, President of Dynex: "We are very pleased to support this
project with M� technology. Dynex has focused on providing robust and
easy to use automated platforms for over 20 years. We continuously
strive to improve the performance and utility of our systems and our new
M� multiplexing technology offers a quantum leap forward in this regard.
This real world application in the DRC demonstrates the efficacy,
robustness and productivity of M�. We look forward to launching this
fully automated multiplex technology in 2014 for any immunoassay
application requiring increased throughput and lower cost per test."

Dynex and UCLA will continue to collaborate on the DRC health survey,
testing a further 7,500 samples taken from across the country through
the first quarter of 2014. More information on M� technology can be
found at www.dynextechnologies.com.

About Dynex Technologies: Dynex pioneered microplate technology
more than 50 years ago, and has since delivered a series of cutting
edge, best-of-class processing systems, including the 4-plate DSX®
and 2-plate DS2 (News - Alert)® systems, and the newly released Agility®
high throughput system. Dynex's patented M� multiplexed microwell
technology combines ELISA-based assay technology with the cost and time
saving benefits of multiplexed assays in a fully automated system,
delivering superior reproducibility and sensitivity. Dynex designs each
of its products to meet the rigorous demands of scientists in clinical,
biomedical, and pharmaceutical development applications. Dynex is based
in Chantilly, Virginia, USA, with locations in Hong Kong, Germany and
the UK, and markets its products worldwide.

IoT Evolution World NewsKen Briodagh, IoT Evolution World Editorial Director, gives you the download on today’s top news stories from the IoT. Visit IoTEvolutionWorld.com for all the industry news you need to get informed and grow your business.

IoT Evolution World NewsKen Briodagh, IoT Evolution World Editorial Director, gives you the download on today’s top news stories from the IoT. Visit IoTEvolutionWorld.com for all the industry news you need to get informed and grow your business.

IoT Evolution World NewsKen Briodagh, IoT Evolution World Editorial Director, gives you the download on today’s top news stories from the IoT. Visit IoTEvolutionWorld.com for all the industry news you need to get informed and grow your business.Posted Wednesday, July 1, 2015

IoT Evolution World NewsKen Briodagh, IoT Evolution World Editorial Director, gives you the download on today’s top news stories from the IoT. Visit IoTEvolutionWorld.com for all the industry news you need to get informed and grow your business.